Evidence map›Paper›PMID 15831718›Full record

ArticleScience (New York, N.Y.)2005

Diversity of the human intestinal microbial flora.

Paul B Eckburg, Elisabeth M Bik, Charles N Bernstein, Elizabeth Purdom, Les Dethlefsen, Michael Sargent, Steven R Gill, Karen E Nelson, David A Relman

10 registry-linked trialsAbstract read
In one paragraph

Article in Science (New York, N.Y.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 10 registered trials, which are not on this map. Cited by 3,583 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3,583citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04046822 phase4unknown statusstarted 2019, after this paper: background citation

Could Gut Microbiome Contribute to the Therapeutic Effect of Liraglutide 3.0 mg? A Randomized Double Blind Placebo Controlled Trial

Ran2019Enrolled70Registered outcomes21Posted comparisons0ConditionsMicrobiome, Obesity, Weight LossArmsLiraglutide 6 MG/ML [Saxenda], Placebo
Open the trial in the graph
NCT00870012 nacompletednot on this mapstarted 2009, after this paper: background citation

Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics

TypeinterventionalSponsorChinese University of Hong KongRan2009 to 2012Enrolled20ConditionsNonalcoholic Fatty Liver DiseaseArmsLepicol probiotic & prebiotic formula, Simple lifestyle advice
NCT02223468 completednot on this mapstarted 2016, after this paper: background citation

Prospective Study To Characterize The Human Microbiota In Liver Transplantation And Its Impact On Early Outcome

TypeobservationalSponsorHospital Vall d'HebronRan2016 to 2021Enrolled40ConditionsIntestinal Microbiota, Complication of Transplanted Liver, Acute Rejection of Liver Transplant, Infection
NCT03232099 nacompletednot on this mapstarted 2016, after this paper: background citation

Evaluation of Red Wine Effects Upon Gut Flora and Plasma Levels of Trimethylamine-N-oxide (TMAO) in Patients With Established Atherosclerotic Disease

TypeinterventionalSponsorUniversity of Sao Paulo General HospitalRan2016 to 2018Enrolled42ConditionsTrimethylamine-N-oxide, Gut Microbiota, Effects of Red Wine, AtherosclerosisArmsRed Wine consumption, Period without alcohol consumption
NCT03388411 completednot on this mapstarted 2017, after this paper: background citation

Nutritional Intake, Metabolic Abnormalities and Gut Microbiome in Children

TypeobservationalSponsorHallym University Kangnam Sacred Heart HospitalRan2017 to 2018Enrolled61ConditionsObesity, ChildhoodArmsGut microbiome profiling
NCT03611140 nacompletednot on this mapstarted 2014, after this paper: background citation

Effect of a Dietary Portfolio (PD) (Nopal, Chia, Soy, Oat and Inulin) and Physical Activity on Gut Microbiota in Patients With Metabolic Syndrome

TypeinterventionalSponsorInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranRan2014 to 2018Enrolled72ConditionsMetabolic SyndromeArmsDP, Placebo
NCT03766321 naactive not recruitingnot on this mapstarted 2020, after this paper: background citation

Interplay Between Gut Microbiota and Adaptive Immunity in Amyotrophic Lateral Sclerosis: a Clinical Trial

TypeinterventionalSponsorAzienda Ospedaliero-Universitaria di ModenaRan2020 to 2025Enrolled42ConditionsAmyotrophic Lateral SclerosisArmsFecal microbiota transplantation, Placebo
NCT05637021 unknown statusnot on this mapstarted 2022, after this paper: background citation

Study on the Influencing Factors of Intestinal Microecology Changes Before and After Colonoscopy

TypeobservationalSponsorZhongshan Hospital Xiamen UniversityRan2022 to 2022Enrolled38ConditionsColonoscopy, Gastrointestinal Microbiome, Appendix, Carbon Dioxide InsufflationArmsCarbon dioxide insufflated during colonoscopy
NCT06355583 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial

TypeinterventionalSponsorImperial College LondonRan2024 to 2027Enrolled50ConditionsAcute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic LeukemiaArmsEBX-102, Placebo
NCT07704255 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Study on the Effect of Fecal Microbiota Transplantation on Eradication of Refractory Helicobacter Pylori Infection

TypeinterventionalSponsorSichuan Provincial People's HospitalRan2026 to 2026Enrolled10ConditionsHelicobacter Pylori InfectionArmstransanal fecal bacteria transplant
3 · Its place in the literature

Who cites it

3,583 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Zearalenone exposure and the mammalian gut microbiome: a systematic review of the literature.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Pooled it
  3. Pooled it
  4. Global Microbiome: Core and Unique Signatures Across Diverse Populations.International journal of molecular sciences · 2026
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Gut microbes · 2026
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

3,523 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Paul B EckburgDivision of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Room S-169, 300 Pasteur Drive, Stanford CA 94305-5107, USA. eckburg1@stanford.edu
Elisabeth M Bik
Charles N Bernstein
Elizabeth Purdom
Les Dethlefsen
Michael Sargent
Steven R Gill
Karen E Nelson
David A Relman

Funding

Crohn's Disease: Microflora Analysis and Host ResponseR01AI051259 · NIAID · STANFORD UNIVERSITY · PI RELMAN, DAVID ARNOLD · 2002 to 2005
$1.2M
NIAID NIH HHS AI51259NIAID NIH HHS R01 AI051259
6 · The paper itself

Abstract

The human endogenous intestinal microflora is an essential "organ" in providing nourishment, regulating epithelial development, and instructing innate immunity; yet, surprisingly, basic features remain poorly described. We examined 13,355 prokaryotic ribosomal RNA gene sequences from multiple colonic mucosal sites and feces of healthy subjects to improve our understanding of gut microbial diversity. A majority of the bacterial sequences corresponded to uncultivated species and novel microorganisms. We discovered significant intersubject variability and differences between stool and mucosa community composition. Characterization of this immensely diverse ecosystem is the first step in elucidating its role in health and disease.

Indexed as

BiodiversityAdultBacteriaBacteroidetesColonDNA, RibosomalEcosystemFecesGenes, ArchaealGenes, BacterialGenes, rRNAGenetic VariationHumansIntestinal MucosaMethanobrevibacterMiddle AgedDNA, RibosomalRNA, Ribosomal, 16S

Identifiers

PMID15831718
PMCPMC1395357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 4 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.